Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradicati
- PDF / 685,559 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 20 Downloads / 201 Views
ORIGINAL ARTICLE
Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication Lian‑Di Kan1 · Jie Chen1 · Yue‑Ting Huang1 · Yang Qiu1 · Xin‑Lu Yu1 · Hong‑Mei Fang1 · Qin Chen1 · Liu‑Cheng Li1 Received: 20 May 2020 / Accepted: 29 June 2020 © Springer Nature Switzerland AG 2020
Abstract To evaluate the efficacy and economics of different proton pump inhibitors (PPIs) combined with bismuth quadruple regimens for Helicobacter pylori (Hp) eradication, a retrospective analysis method was used to collect Hp-positive patients who were treated with a bismuth-containing quadruple regimen (PPIs + amoxicillin + furazolidone + colloid pectin bismuth) from the outpatient department of gastroenterology in our hospital from January to June 2017. A total of 1410 patients were included in the study and divided into four groups according to different PPIs: group A (pantoprazole sodium enteric-coated capsules, 352 cases), group B (esomeprazole magnesium enteric-coated tablets, 462 cases), group C (pantoprazole sodium enteric-coated tablets, 392 cases) and group D (rabeprazole sodium enteric-coated tablets, 204 cases). The eradication rate of Hp and cost-saving in each group were then compared. There were no significant differences of gender (P = 0.526) and age (P = 0.366) between each Hp treatment regimen. The eradication rates of groups A, B, C and D were 91.48%, 89.83%, 86.73% and 90.69%, respectively. No statistical differences of Hp eradication rates were observed between each group yet (P > 0.05). However, the cost of group A was the lowest. In the present study, the Hp eradication rates between different PPIs regimens were similar in treating Hp infection. Nevertheless, the point in favor of pantoprazole capsules is the slightly higher Hp eradication rate and lower drug cost than other PPIs, which provides a significant evidence for the clinical medication decision in treating Hp infection. Keywords Helicobacter pylori · Proton pump inhibitors · Bismuth · Eradication rate · Cost Abbreviations Hp Helicobacter pylori PPIs Proton pump inhibitors UBT Urea breath test Bid Bis in diē/twice a day
Introduction Helicobacter pylori (Hp) is a Gram-negative microaerobic bacterium that is closely related to various gastrointestinal diseases including gastric ulcer, duodenal ulcer, chronic Lian-Di Kan and Jie Chen have contributed equally to this work. * Liu‑Cheng Li [email protected] 1
Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No. 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China
gastritis, gastric mucosal lesions and gastric cancer [1]. According to global statistics in 2018, the lowest prevalence rate of Hp infection was in Oceania (24.4%), while the highest was in Africa (79.1%) [2]. The number of people infected in China has reached 768 million, accounting for 55.8% of the total population of China [3]. Hp-infected individuals have a 10% to 20% risk of peptic ulcers and a 1% to 2% risk of gastric ca
Data Loading...
